Prostate cancer decisions — 2024

The Veteran's bilateral pulmonary nodules, coronary artery disease, prostate cancer, and aortic aneurysm are all granted service connection due to exposure to herbicide agents. The effective date is not specified as the decision was for initial ratings.

The Veteran's prostate cancer is being remanded for further evaluation due to the need for a medical opinion regarding its relationship to service, specifically his exposure at Camp LeJeune.

The Veteran's prostate cancer and coronary artery disease are presumed to be related to his in-service exposure to herbicides, specifically Agent Orange. As such, the claims for service connection are granted.

The Veteran's claim for an effective date of March 1, 2020, but no earlier, for the award of service connection for prostate cancer with urinary frequency and hesitancy is granted. The delay in filing his claim was due to the COVID-19 pandemic.

The Board has determined that new and relevant evidence has been received with respect to the previously denied service connection claim for prostate cancer. The Veteran's rheumatoid arthritis claim is also remanded for further review.

The Board has decided to reduce the Veteran's prostate cancer rating from 100% to 60%, effective July 1, 2024. The issue of a separate rating for surgical scars related to prostatectomy is remanded due to inadequate examination.

The Board has denied the Veteran's claims for service connection for PTSD, residuals of a broken nose, sterility, and prostate cancer. The claims for left hip disability, right hip disability, left ankle disability, right ankle disability, right knee disability, and eye disability are remanded for further development.

The Board has remanded the case due to insufficient evidence regarding the Veteran's exposure to toxic substances during service, specifically asbestos. The Veteran is considered a Persian Gulf War Veteran but lacks a TERA memorandum detailing his specific exposures.

The Veteran's claim for an earlier effective date for prostate cancer service connection was denied as no formal or informal claim was received prior to August 18, 2020.

The Veteran's prostate cancer residuals are rated at a 20 percent disability rating prior to May 1, 2024. From May 1, 2024, the Veteran is entitled to a 40 percent disability rating.,During the pendency of this appeal, the evidence presented at the May 1, 2024, Board hearing shows an increase in severity of the Veteran's symptomology.

The Veteran's appeal for a higher rating for his prostate cancer residuals, which included cystitis with hematuria, was denied. The VA determined that the current 60 percent rating adequately reflected the severity of the disability.

The Board denied the Veteran's claim for service connection for prostate cancer, finding no causal relationship between his current condition and in-service exposure to chemical or herbicide agents. The evidence did not support a nexus between the Veteran's prostate cancer and his documented toxic exposure.

The Board has granted service connection for coronary artery disease and prostate cancer, both of which are presumed to be related to herbicide agent exposure during the Veteran's active duty in Thailand. The Board also denied service connection for bilateral hearing loss due to lack of evidence linking it to service.

The Veteran's appeal was dismissed because the Notice of Disagreement (NOD) did not identify a specific decision or issue with which he disagreed. The NOD was filed in October 2021, but there is no January 2021 rating decision that the Veteran could have appealed.

The Veteran's prostate cancer is granted as a result of the PACT Act presumption, but the issue of service connection on other grounds remains pending and requires further examination.

The Board has determined that the Veteran's application for Legacy S-DVI is remanded due to procedural errors in determining his 'good health' based on his service-connected and non-service-connected conditions.

The Board has remanded the claims for service connection for bladder cancer and prostate cancer due to a lack of authorization from the Veteran for private medical records. The VA must assist in obtaining these records.

The Veteran's claims for service connection were granted. Erectile dysfunction, tinnitus, and diabetes mellitus, type II are all granted due to herbicide exposure under the PACT Act. Prostate cancer is also granted due to herbicide exposure. Service connection for hearing loss and peripheral neuropathy of the lower extremities (secondary to diabetes) was denied.

Service connection has been granted for prostate cancer, lung disorder (asthma with lung nodule), chronic kidney disease, and sinonasal polyposis (claimed as residuals of plasma cytoma) due to exposure to herbicides during service.

The Board has remanded the case due to inadequate medical opinion regarding the cause of death and negligence in treatment. The Veteran's cause of death is being reviewed for potential service connection under new evidence.